Survival outcomes of patients with advanced melanoma from 2013 to 2017: Results of a nationwide population-based registry

M.C.T. van Zeijl, L.C. de Wreede, A.J.M. van den Eertwegh, M.W.J.M. Wouters, A. Jochems, M.G. Schouwenburg, M.J.B. Aarts, A.C.J. van Akkooi, F.W.P.J. van den Berkmortel, J.W.B. de Groot, G.A.P. Hospers, E. Kapiteijn, D. Piersma, R.S. van Rijn, K.P.M. Suijkerbuijk, A.J. Ten Tije, A.A.M. van der Veldt, G. Vreugdenhil, J.J.M. van der Hoeven, J.B.A.G. Haanen

Research output: Contribution to journalArticleAcademicpeer-review

3 Citations (Web of Science)
Original languageEnglish
Pages (from-to)242-251
Number of pages10
JournalEuropean Journal of Cancer
Volume144
DOIs
Publication statusPublished - 1 Feb 2021

Keywords

  • advanced melanoma
  • combined nivolumab
  • double-blind
  • immunotherapy
  • ipilimumab
  • iv melanoma
  • metastatic melanoma
  • nationwide
  • pembrolizumab
  • phase-iii trials
  • pooled analysis
  • population-based
  • progression-free
  • real-world
  • targeted therapy
  • vemurafenib
  • Targeted therapy
  • Real-world
  • Advanced melanoma
  • Nationwide
  • METASTATIC MELANOMA
  • Population-based
  • Immunotherapy
  • IV MELANOMA
  • POOLED ANALYSIS
  • VEMURAFENIB
  • COMBINED NIVOLUMAB
  • PEMBROLIZUMAB
  • DOUBLE-BLIND
  • PROGRESSION-FREE
  • PHASE-III TRIALS
  • IPILIMUMAB

Cite this